Strategic Acquisition ZEUS Scientific has been acquired by Sebia, signaling backing from a larger diagnostics group and potential access to expanded channels, distribution networks, and cross-sell opportunities for autoimmune, infectious disease, and novel biomarkers.

Expanded Biomarkers The launch of AccuCardia for sPLA2-IIA as a predictive cardiac biomarker opens a door to cardiometabolic risk assessment collaborations, lab panels, and integration with Sebia’s broader diagnostic portfolio.

Lyme Disease Innovation Recent FDA-cleared modified two-tiered Lyme testing algorithm positions ZEUS as a leader in improving early detection, enabling direct sales opportunities to labs seeking enhanced infectious disease diagnostics and recurring instrument utilization.

Integrated Diagnostic Systems Product launches like the dIFine 30 System and SP30 slide processor indicate a push toward integrated digital immunofluorescence workflows, offering cross-sell potential with Sebia customers needing turnkey automation and high-throughput capabilities.

SMB Focused Growth With a small to mid-sized employee base and a revenue range of 10–25 million, ZEUS/Sebia can target regional hospitals and diagnostic labs seeking cost-effective, high-value autoimmune and infectious disease solutions with scalable support and service.